BMO Capital analyst Gary Nachman downgraded Horizon Therapeutics (HZNP) to Market Perform from Outperform with a $117 price target. The company’s acquisition by Amgen (AMGN) reflects a fair value for a "solid growth story" and he does not anticipate any major hurdles from the standpoint of the FTC, the analyst tells investors in a research note.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on HZNP:
- John Paulson Hits the Jackpot With Horizon Buyout — Here Are His 2 Top Stocks Right Now
- Amgen deal yields nice accretion but large debt position, says Baird
- Horizon Therapeutics downgraded to Equal Weight from Overweight at Wells Fargo
- Horizon Therapeutics downgraded to Neutral from Buy at Guggenheim
- Amgen price target raised to $299 from $297 at Piper Sandler
